Matsupexole

Pharmaceutical compound From Wikipedia, the free encyclopedia

Matsupexole (INNTooltip International Nonproprietary Name; developmental code names AM006 and KDT-3594) is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease.[1][3][2][4][5] It is taken orally.[1][2]

Other namesMatsupexol; AM006; AM-006; KDT-3594; KDT3594
Routes of
administrationOral[1][2]
Drug classDopamine receptor agonist; Dopamine D2 and D3 receptor agonist
CAS Number
Quick facts Clinical data, Other names ...
Matsupexole
Clinical data
Other namesMatsupexol; AM006; AM-006; KDT-3594; KDT3594
Routes of
administration		Oral[1][2]
Drug classDopamine receptor agonist; Dopamine D2 and D3 receptor agonist
Identifiers
  • (4aR,6R,8aR)-2-amino-3-cyano-N-[2-(dimethylamino)ethylcarbamoyl]-8-methyl-N-propyl-4a,5,6,7,8a,9-hexahydro-4H-thieno[3,2-g]quinoline-6-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H34N6O2S
Molar mass446.61 g·mol−1
3D model (JSmol)
  • CCCN(C(=O)[C@@H]1C[C@@H]2CC3=C(C[C@H]2N(C1)C)SC(=C3C#N)N)C(=O)NCCN(C)C
  • InChI=1S/C22H34N6O2S/c1-5-7-28(22(30)25-6-8-26(2)3)21(29)15-9-14-10-16-17(12-23)20(24)31-19(16)11-18(14)27(4)13-15/h14-15,18H,5-11,13,24H2,1-4H3,(H,25,30)/t14-,15-,18-/m1/s1
  • Key:PJYJWXOMQPHSKB-IIDMSEBBSA-N
Close

The drug is a non-ergoline derivative related to pramipexole and acts as a dopamine D2 and D3 receptor agonist.[5][4][6] It has far lower selectivity for the dopamine D3 receptor over the dopamine D2 receptor than pramipexole and other non-ergoline dopamine receptor agonists.[5] Relatedly, whereas pramipexole and other non-ergoline dopamine receptor agonists like ropinirole and rotigotine produce somnolence in humans and pramipexole has been found to strongly promote non-REM sleep in rodents, these side effects being associated with dopamine D3 receptor agonism, matsupexole and cabergoline did not promote non-REM sleep at efficacious antiparkinsonian doses in rodents.[5] This may be due to a better balance of wakefulness-promoting dopamine D2 receptor activation versus sedating dopamine D3 receptor activation.[5] Similarly to pramipexole, but unlike cabergoline, matsupexole showed negligible activity as a serotonin 5-HT2B receptor agonist and hence is not thought to have a risk of cardiac valvulopathy.[5]

Matsupexole was first described in the scientific literature by 2017.[7] It originated by Kissei Pharmaceutical and is being developed by Kissei Pharmaceutical and AffaMed Therapeutics in Japan and China.[1][3][2] As of August 2025, the drug is in phase 2 clinical trials.[1][3][2] Matsupexole is described by its developers as a potential best-in-class dopamine receptor agonist for Parkinson's disease.[5]

See also

References

Related Articles

Wikiwand AI